By Dean Seal
Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell lung cancer.
The stock was up 12% at $2.10 in premarket trading. Shares had fallen 22% year-to-date when the market closed Wednesday.
The biotechnology company said before the bell that mature survival data for patients treated with the combination were well above historical controls and exceeded expectations.
"We are encouraged to see Efti build upon the historical clinical outcomes from the most widely used immunotherapy-chemo combination today," Chief Executive Marc Voigt said.
Early evaluations of an expanded cohort of trial patients are also tracking well, Voigt said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 14, 2024 09:10 ET (14:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。